Hepatic De Novo Lipogenesis (DNL)in the Pathogenesis of Hepatic Steatosis in Obese Youth

Conditions

Fatty Liver | Hepatic Steatosis

Trial Phase

Trial Purpose and Description

Trial Purpose

Nonalcoholic Fatty Liver Disease (NAFLD) is becoming the most common cause of liver disease in pediatrics, but little is known about its pathophysiology in children. While studies in obese adults with hepatic steatosis have described an increased hepatic de novo lipogenesis (DNL) depending on the diet, there are no studies exploring the mechanisms by which excess hepatic triglycerides increases in obese youths, thus explaining the accompanying dyslipidemia and the metabolic syndrome. The central hypothesis of this study is that hepatic conversion of carbohydrates to lipid (DNL) is enhanced and associated with accumulation of excess liver fat, dyslipidemia and hepatic insulin resistance in obese youths with hepatic steatosis. The overall goal is to examine whether hepatic DNL is increased in obese youths with steatosis compared to matched controls without steatosis.

Hypotheses: Hepatic conversion of carbohydrates to lipid (DNL) is enhanced and is associated with accumulation of excess liver fat, dyslipidemia and hepatic insulin resistance in obese youths with hepatic steatosis.


Participation Guidelines

Age:
12 Years - 18 Years
Gender:
Both

Eligibility Criteria

Inclusion Criteria:

- Cases will meet the following criteria:

- Age between 12 and 18 years

- BMI higher than 85th percentile

- Hepatic fat fraction (the amount of fat into the liver) greater or equal than
5.5%

- Absence of any endocrinopathy

- Absence of any therapy with medication known to alter glucose metabolism

Controls will meet the following criteria:

- Age between 12 and 18 years

- BMI higher than 85th percentile

- Hepatic fat fraction (the amount of fat into the liver) lower than 5.5%

- Absence of any endocrinopathy

- Absence of any therapy with medication known to alter glucose metabolism

Exclusion Criteria:

- BMI under the 85th percentile

- Hepatic fat fraction (the amount of fat into the liver) less than 5.5%

- Absence of any endocrinopathy

- Any therapy with medication known to alter glucose metabolism

Controls will meet the following criteria:

- BMI under the 85th percentile

- Hepatic fat fraction (the amount of fat into the liver) greater than or equal to 5.5%

- Any endocrinopathy

- Any therapy with medication known to alter glucose metabolism

Sponsor:
National Institute of Child Health and Human Development
Dates:
12/17/2010
Last Updated:
Study HIC#:
1008007192